Automated Surveillance, Alert, and Rapid Diagnosis of Thrombotic Microangiopathies: the ASARD-TMA Study

Launched by FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS · Aug 10, 2023

Keywords

ClinConnect Summary

The ASARD-TMA Study is a clinical trial that aims to improve the way doctors quickly diagnose a serious condition called Thrombotic Microangiopathies (TMA), which can cause problems with blood flow and lead to serious health issues. The researchers are testing an automated system that sends alerts when certain blood test results suggest a high chance of TMA. If a patient in the Emergency Department or another hospital area has specific blood markers indicating they might have TMA, doctors will receive an instant warning. This allows them to evaluate the patient urgently and start necessary tests and treatments more quickly.

To participate in this study, patients should be admitted to the hospital's Emergency room or be inpatients with a suspicion of TMA based on their doctor's evaluation or the automated alerts. The study is open to all adults aged 18 and older. However, patients whose test results show a low likelihood of TMA will not be included. By testing this system across different hospitals, the study hopes to ensure that patients receive timely and effective care, even in smaller hospitals where specialized hematology services may not be available around the clock.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Patients admitted to the Emergency ward or inpatients of the involved Hospitals with suspicion of TMA:
• • Based on the clinical evaluation of the care physicians
• • Based on the alerts issued by the automated algorithm
• Exclusion Criteria:
• • Patients with a predictive probability of TMA \< 90% (6) according to the diagnostic algorithm